| Effective inhibition of MERS-CoV infection by resveratrol | BMC Infectious Diseases | 2017 | 212 |
| Antimicrobial resistance in Africa: a systematic review | BMC Infectious Diseases | 2017 | 180 |
| Risk factors, perceptions and practices associated with Taenia solium cysticercosis and its control in the smallholder pig production systems in Uganda: a cross-sectional survey | BMC Infectious Diseases | 2017 | 172 |
| Global expansion of chikungunya virus: mapping the 64-year history | International Journal of Infectious Diseases | 2017 | 144 |
| Carbapenem resistance, inappropriate empiric treatment and outcomes among patients hospitalized with Enterobacteriaceae urinary tract infection, pneumonia and sepsis | BMC Infectious Diseases | 2017 | 118 |
| The Increase in Hospitalizations for Urinary Tract Infections and the Associated Costs in the United States, 1998-2011 | Open Forum Infectious Diseases | 2017 | 114 |
| Self-medication and self-prescription with antibiotics in the Middle East-do they really happen? A systematic review of the prevalence, possible reasons, and outcomes | International Journal of Infectious Diseases | 2017 | 107 |
| Factors Associated with Virological Non-suppression among HIV-Positive Patients on Antiretroviral Therapy in Uganda, August 2014-July 2015 | BMC Infectious Diseases | 2017 | 98 |
| Vaccine Rejection and Hesitancy: A Review and Call to Action | Open Forum Infectious Diseases | 2017 | 95 |
| Novel approaches to tuberculosis vaccine development | International Journal of Infectious Diseases | 2017 | 94 |
| How should we respond to the emergence of plasmid-mediated colistin resistance in humans and animals? | International Journal of Infectious Diseases | 2017 | 89 |
| Quality of tuberculosis care in high burden countries: the urgent need to address gaps in the care cascade | International Journal of Infectious Diseases | 2017 | 86 |
| Tuberculosis stigma as a social determinant of health: a systematic mapping review of research in low incidence countries | International Journal of Infectious Diseases | 2017 | 85 |
| Preventive therapy for latent tuberculosis infection-the promise and the challenges | International Journal of Infectious Diseases | 2017 | 85 |
| Candida auris: An emerging multidrug-resistant pathogen | International Journal of Infectious Diseases | 2017 | 82 |
| Invasive Mold Infections (IMIs) of the Central Nervous System (CNS) in Patients with Hematologic Cancer (HC) (2000–2016): Uncommon but Deadly | Open Forum Infectious Diseases | 2017 | 78 |
| The Epidemiology of Non-tuberculous Mycobacteria (NTM) from Non-pulmonary Sites over 4 Years in Nebraska | Open Forum Infectious Diseases | 2017 | 78 |
| Pharmacodynamic Optimization for the Treatment of Invasive Candida auris Infection | Open Forum Infectious Diseases | 2017 | 78 |
| Primary or Secondary Prophylaxis with Voriconazole Compared with Posaconazole for Prevention of Invasive Fungal Infections After Hematopoietic Stem Cell Transplantation | Open Forum Infectious Diseases | 2017 | 78 |
| Wide Range of Carbapenem-resistant Enterobacteriaceae Incidence and Trends in Emerging Infections Program Surveillance, 2012–2015 | Open Forum Infectious Diseases | 2017 | 78 |
| Invasive Mold Infections (IMI) among Liver Transplant Recipients (LTR): Is It Time to Reconsider the Risk Factors that Determine Antifungal Prophylaxis? | Open Forum Infectious Diseases | 2017 | 78 |
| Clinical Comparison between Native Vertebral Osteomyelitis with Abscess vs Without Abscess in Clinical Features and Outcomes | Open Forum Infectious Diseases | 2017 | 78 |
| Antimicrobial Activity of Ceftazidime-Avibactam Tested against Multidrug-Resistant Enterobacteriaceae and Pseudomonas aeruginosa Isolates from United States (US) Medical Centers (2013–2016) | Open Forum Infectious Diseases | 2017 | 78 |
| Human Target Attainment Probabilities for Delafloxacin against Escherichia coli and Pseudomonas aeruginosa | Open Forum Infectious Diseases | 2017 | 78 |
| The Development and Assessment of a Physician-Specific Antibiotic Usage and Spectrum Feedback Tool | Open Forum Infectious Diseases | 2017 | 78 |
